Relmada Raises $3M to Develop LevoCap Painkiller
Relmada Therapeutics today announced that $3 million in Series A proceeds from stakeholders and investors will be used to continue the development of the opioid LevoCap.
Providing a once-daily extended release dosage of levorphanol, LevoCap is intended to treat chronic pain and potentially reverse a patient's analgesic tolerance to morphine.
Relmada anticipates launching a Phase 3 study for the drug in 2013, according to CEO Sergio Traversa.
Related Articles on Pain Management:
Middle Fork Surgery Center Visited by Oregon's Co-Speaker of the HouseDr. Daniel Carr Named PAINWeek 2012 Keynote Speaker
Neurostimulation Field Draw Investor Attention
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the latest ASC news and feature stories from Becker's ASC Review, sign-up for the free Becker's ASC Review E-weekly by clicking here.
© Copyright ASC COMMUNICATIONS 2012. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.
To receive the free Becker's Operating Room Clinical Quality & Infection Control
E-Weekly, which focuses on clinical quality, infection control, patient safety and accreditation, click here.
Latest Articles
- House Votes to Repeal the PPACA — for 37th Time
- 6 Statistics on Concierge and Direct Pay Physician Practices
- Best Practices: Documentation and Reporting for Post-Operative Pain Management Procedures in Anesthesia
- 5 Things to Know About Medical Office Visits in 2012
- Medical Facilities Corporation Reports Higher Revenue After Arkansas Surgical Hospital Acquisition